MEDWELL ANNOUNCES MIMETOGEN UPDATES

EDMONTON, Alberta - September 12, 2014 - Medwell Capital Corp. ("Medwell") (TSX-V: MWC) announces that Mimetogen has announced top line results from its second clinical trial, as well as the expiration of an exclusive option to license its MIM-D3 compound. For more information please go to www.mimetogen.com . Additional information on Mimetogen's clinical trials can be found at www.clinicaltrials.gov.

"It is observed that it is usual in the dry eye space, where trials need to establish efficacy on two endpoints (both sign and symptoms), for development programs to require multiple trials and patient investors," says Kevin Giese, President of Medwell. "While it is evident that Mimetogen's optionee had an opportunity to review the trial data and has chosen to let the option expire, it is Mimetogen's stated position that based on positive signals seen in both clinical trials, as well as meetings with its advisors and the FDA, it has a clear development path that it intends to pursue."

ON BEHALF OF THE BOARD OF DIRECTORS OF MEDWELL CAPITAL CORP.

"Kevin Giese"
President, CEO & Chairman

About Medwell Capital Corp.

Medwell Capital Corp. is a Canadian-based investment and advisory firm. For further information please visit www.medwellcapital.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

distributed by